Laprazol Fastab

Lansoprazole, the active ingredient in Laprazol Fastab, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to manage conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, and other acid‑related disorders in adults.

GNH USA supplies Laprazol Fastab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export. Customers benefit from reliable logistics and on‑time delivery across multiple continents.

Lansoprazole is indicated for several acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining higher gastric pH. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence by suppressing acid secretion. - Helicobacter pylori eradication regimens: used in combination therapy to increase antibiotic effectiveness against H. pylori infection. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild pain often transient. - Diarrhea: loose stools, usually self‑limiting. - Nausea: feeling of sickness. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Clostridioides difficile infection: severe colitis with diarrhea. - Elevated liver enzymes: indication of hepatic stress. - Hypomagnesemia: low magnesium levels with prolonged use. - Bone fractures: increased risk with long‑term therapy. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions.

Before prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: adjust use in patients with severe impairment. - Use with caution in the elderly: higher incidence of fractures and infections. - Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion. - Monitor long‑term users for vitamin B12 deficiency: periodic testing recommended. - Review concomitant medications: potential for drug‑drug interactions. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several medicines; awareness of interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Clarithromycin: increased plasma levels of clarithromycin and risk of toxicity. - Ketoconazole: reduced absorption of ketoconazole leading to therapeutic failure. - Atazanavir: decreased atazanavir exposure, compromising HIV treatment. - HIV protease inhibitors (e.g., ritonavir): diminished antiviral efficacy. - Methotrexate: elevated methotrexate concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Digoxin: increased digoxin levels, watch for signs of toxicity. - Phenytoin: altered phenytoin metabolism, adjust dosing as needed. - Diazepam: possible increased sedation, assess patient response. - Theophylline: reduced clearance, monitor for toxicity.